Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
E-7820 by Eisai for Chronic Myelomonocytic Leukemia (CMML): Likelihood of Approval
E-7820 is under clinical development by Eisai and currently in Phase II for Chronic Myelomonocytic Leukemia (CMML). According to GlobalData,...